CliffBio
small molecule

AFINITOR

EVEROLIMUS

Loss of exclusivityJuly 2028latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand nameAFINITOR
Active ingredientEVEROLIMUS
Strength2.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2010
Marketing statusRX

Listed patents

PatentExpiresType
9006224July 2028use U-1681
8410131*PEDMay 2026—
8410131November 2025use U-1368

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AFINITOR patent cliff — loss of exclusivity July 2028 | CliffBio